<p>Sentinel Trust Co. LBA 在第三季度购买了瑞士罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）的披露。该基金购买了 21,507 股公司股票，价值约为 878,000 美元。</p>
<ul>
<li>3 只投资超过 1000 亿美元的大型制药股。</li>
</ul>
<p>其他几家机构投资者和对冲基金也对该股票的持仓进行了调整。Oakworth Capital Inc. 在第三季度以约 57,000 美元的价格收购了罗氏的新股份。First Horizon Advisors Inc. 在第二季度将其在罗氏的股份增加了 81.2%。First Horizon Advisors Inc. 现在拥有 1,843 股公司股票，价值 75,000 美元，此前在上个季度又购买了 826 股。Salomon &amp; Ludwin LLC 在第三季度将其在罗氏的持股增加了 256.6%。Salomon &amp; Ludwin LLC 现在拥有 2,853 股公司股票，价值 129,000 美元，此前在上个季度又购买了 2,053 股。Enterprise Financial Services Corp 在第二季度以 208,000 美元的价格收购了罗氏的新股份。最后，FineMark National Bank &amp; Trust 在第二季度以约 210,000 美元的价格收购了罗氏的新股份。</p>
<h2>罗氏公司新闻要点</h2>
<p>以下是本周影响罗氏的主要新闻：</p>
<ul>
<li>积极情绪：罗氏报告了强劲的 2025 年业绩——销售增长 7%——并预计 2026 年将实现中个位数的销售增长和高个位数的核心每股收益增长；管理层还计划提高股息，以支持长期股东价值。临时公告：罗氏报告 2025 年业绩强劲，销售增长 7%。</li>
<li>积极情绪：罗氏的产品管线——尤其是肥胖和心血管项目——被认为是潜在的增长驱动因素，并在 GLP-1 市场中构成了可信的竞争者，支撑了长期上涨的 “买入” 论点。罗氏的全年收益：稳健，无警报——肥胖承诺使买入论点成立。</li>
<li>中性情绪：收益基本符合预期，未能激发市场热情，导致股票在投资者等待更清晰的产品管线变现证据时保持区间波动。制药公司罗氏和赛诺菲谈论其产品管线，但收益未能激发市场热情。</li>
<li>中性情绪：高盛对罗氏（RHHVF/RHHBY）给予 “持有” 评级，反映出中立观点，可能限制了尽管前景乐观但仍然有限的买入兴趣。罗氏控股公司（RHHVF）获得高盛的持有评级。</li>
<li>消极情绪：货币（外汇）逆风对报告结果产生了重大影响，降低了基础增长的表面影响，并造成了短期收益的不确定性，给股票带来了压力。罗氏的年度业绩受到货币逆风的影响。</li>
</ul>
<h2>罗氏股票表现</h2>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>RHHBY 的股票在周五开盘价为 56.75 美元。该公司的债务与股本比率为 0.80，速动比率为 1.02，流动比率为 1.29。罗氏控股公司的 12 个月低点为 34.75 美元，12 个月高点为 57.29 美元。该公司的 50 日简单移动平均线为 51.76 美元，200 日简单移动平均线为 45.39 美元。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对该公司发表了看法。巴克莱在 1 月 6 日的研究报告中将罗氏的评级从 “持平” 上调至 “增持”。花旗在周二的研究报告中开始覆盖罗氏，并对该公司给予 “买入” 评级。德意志银行在 11 月 11 日的研究报告中将罗氏的评级从 “卖出” 上调至 “持有”。摩根士丹利在 12 月 2 日的研究报告中重申了对罗氏股票的 “减持” 评级。最后，高盛在 1 月 15 日的报告中将罗氏的评级从 “卖出” 上调至 “持有”。两位股票研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，罗氏的共识评级为 “适度买入”，共识目标价为 57.00 美元。</p>
<ul>
<li>NVIDIA 投资了这两只人工智能股票，你应该投资吗？</li>
</ul>
<p><strong>获取我们对罗氏的最新分析</strong></p>
<h2>罗氏公司简介</h2>
<p>（免费报告）</p>
<p>罗氏控股公司是一家总部位于巴塞尔的瑞士跨国医疗保健公司，成立于 1896 年，由弗里茨·霍夫曼 - 拉·罗氏创立。该公司主要通过两个互补的部门运营——制药和诊断，并以将药物开发与诊断能力相结合以推动个性化医疗而闻名。在美国和其他国际市场，股票以美国存托凭证的形式交易，代码为 RHHBY OTCMKTS: RHHBY。</p>
<p>在制药领域，罗氏专注于开发和商业化处方药，涵盖包括肿瘤学、免疫学、传染病和神经科学等治疗领域，特别强调靶向生物制剂和个性化疗法。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>股票市场传奇警告：“市场即将迎来不祥的一天……”</li>
<li>你需要拥有黄金的另一个理由… [即将耗尽]</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>新消息：黄金创历史新高</li>
<li>德意志银行刚刚将其黄金目标上调至 6,000 美元</li>
</ul>
<p><strong>想看看其他对冲基金持有的 RHHBY 吗？</strong> 访问 HoldingsChannel.com，获取罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在罗氏吗？</h2>
<p>在考虑罗氏之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而罗氏并不在名单上。</p>
<p>虽然罗氏目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Sentinel Trust Co. LBA 在第三季度收购了 21,507 股罗氏控股公司（OTCMKTS:RHHBY），价值约 878,000 美元，已向美国证券交易委员会（SEC）披露。其他机构投资者也调整了在罗氏的持仓。该公司报告了强劲的 2025 年业绩，销售增长达到 7%，并计划提高股息。然而，汇率波动对收益产生了影响，导致分析师的情绪趋于中性，高盛给予了 “持有” 评级。罗氏的股票共识评级为 “适度买入”，目标价格为 57.00 美元</p>

<p>Sentinel Trust Co. LBA purchased a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 21,507 shares of the company's stock, valued at approximately $878,000.</p>
<div class="lb-trans"><p>Sentinel Trust Co. LBA 在第三季度购买了瑞士罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）的披露。该基金购买了 21,507 股公司股票，价值约为 878,000 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只投资超过 1000 亿美元的大型制药股。</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also made changes to their positions in the stock. Oakworth Capital Inc. acquired a new stake in Roche in the 3rd quarter valued at about $57,000. First Horizon Advisors Inc. increased its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company's stock worth $75,000 after acquiring an additional 826 shares during the last quarter. Salomon &amp; Ludwin LLC increased its holdings in Roche by 256.6% in the third quarter. Salomon &amp; Ludwin LLC now owns 2,853 shares of the company's stock worth $129,000 after buying an additional 2,053 shares during the last quarter. Enterprise Financial Services Corp acquired a new position in Roche during the second quarter worth $208,000. Finally, FineMark National Bank &amp; Trust acquired a new position in Roche during the second quarter valued at approximately $210,000.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也对该股票的持仓进行了调整。Oakworth Capital Inc. 在第三季度以约 57,000 美元的价格收购了罗氏的新股份。First Horizon Advisors Inc. 在第二季度将其在罗氏的股份增加了 81.2%。First Horizon Advisors Inc. 现在拥有 1,843 股公司股票，价值 75,000 美元，此前在上个季度又购买了 826 股。Salomon &amp; Ludwin LLC 在第三季度将其在罗氏的持股增加了 256.6%。Salomon &amp; Ludwin LLC 现在拥有 2,853 股公司股票，价值 129,000 美元，此前在上个季度又购买了 2,053 股。Enterprise Financial Services Corp 在第二季度以 208,000 美元的价格收购了罗氏的新股份。最后，FineMark National Bank &amp; Trust 在第二季度以约 210,000 美元的价格收购了罗氏的新股份。</p>
</div><h2>Key Roche News</h2>
<div class="lb-trans"><h2>罗氏公司新闻要点</h2>
</div><p>Here are the key news stories impacting Roche this week:</p>
<div class="lb-trans"><p>以下是本周影响罗氏的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Roche reported strong 2025 results — 7% sales growth — and guided to mid-single-digit sales growth and high-single-digit core EPS growth for 2026; management also plans to raise the dividend, supporting longer-term shareholder value. Ad-hoc announcement: Roche reports strong 2025 results with 7% sales growth</li>
<li>Positive Sentiment: Roche’s pipeline — especially obesity and cardiovascular programs — is highlighted as a potential growth driver and a credible challenger in the GLP‑1 market, underpinning the “buy” thesis for longer-term upside. Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case</li>
<li>Neutral Sentiment: Earnings essentially matched expectations and failed to excite the market, leaving the stock rangebound as investors await clearer proof of pipeline monetization. Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite</li>
<li>Neutral Sentiment: Goldman Sachs assigned a “Hold” to Roche (RHHVF/RHHBY), reflecting a neutral view that likely limited buying interest despite the upbeat guidance. Roche Holding AG (RHHVF) Gets a Hold from Goldman Sachs</li>
<li>Negative Sentiment: Currency (FX) headwinds materially weighed on reported results, reducing the headline impact of underlying growth and creating near-term earnings uncertainty that pressured the stock. Roche's annual results hit by currency headwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：罗氏报告了强劲的 2025 年业绩——销售增长 7%——并预计 2026 年将实现中个位数的销售增长和高个位数的核心每股收益增长；管理层还计划提高股息，以支持长期股东价值。临时公告：罗氏报告 2025 年业绩强劲，销售增长 7%。</li>
<li>积极情绪：罗氏的产品管线——尤其是肥胖和心血管项目——被认为是潜在的增长驱动因素，并在 GLP-1 市场中构成了可信的竞争者，支撑了长期上涨的 “买入” 论点。罗氏的全年收益：稳健，无警报——肥胖承诺使买入论点成立。</li>
<li>中性情绪：收益基本符合预期，未能激发市场热情，导致股票在投资者等待更清晰的产品管线变现证据时保持区间波动。制药公司罗氏和赛诺菲谈论其产品管线，但收益未能激发市场热情。</li>
<li>中性情绪：高盛对罗氏（RHHVF/RHHBY）给予 “持有” 评级，反映出中立观点，可能限制了尽管前景乐观但仍然有限的买入兴趣。罗氏控股公司（RHHVF）获得高盛的持有评级。</li>
<li>消极情绪：货币（外汇）逆风对报告结果产生了重大影响，降低了基础增长的表面影响，并造成了短期收益的不确定性，给股票带来了压力。罗氏的年度业绩受到货币逆风的影响。</li>
</ul>
</div><h2>Roche Stock Performance</h2>
<div class="lb-trans"><h2>罗氏股票表现</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>Shares of RHHBY opened at $56.75 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.29. Roche Holding AG has a 12 month low of $34.75 and a 12 month high of $57.29. The firm has a fifty day simple moving average of $51.76 and a 200 day simple moving average of $45.39.</p>
<div class="lb-trans"><p>RHHBY 的股票在周五开盘价为 56.75 美元。该公司的债务与股本比率为 0.80，速动比率为 1.02，流动比率为 1.29。罗氏控股公司的 12 个月低点为 34.75 美元，12 个月高点为 57.29 美元。该公司的 50 日简单移动平均线为 51.76 美元，200 日简单移动平均线为 45.39 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have recently weighed in on the company. Barclays raised Roche from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on Roche in a research report on Tuesday. They issued a &#34;buy&#34; rating for the company. Deutsche Bank Aktiengesellschaft upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 11th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a research note on Tuesday, December 2nd. Finally, The Goldman Sachs Group upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Roche has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。巴克莱在 1 月 6 日的研究报告中将罗氏的评级从 “持平” 上调至 “增持”。花旗在周二的研究报告中开始覆盖罗氏，并对该公司给予 “买入” 评级。德意志银行在 11 月 11 日的研究报告中将罗氏的评级从 “卖出” 上调至 “持有”。摩根士丹利在 12 月 2 日的研究报告中重申了对罗氏股票的 “减持” 评级。最后，高盛在 1 月 15 日的报告中将罗氏的评级从 “卖出” 上调至 “持有”。两位股票研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，罗氏的共识评级为 “适度买入”，共识目标价为 57.00 美元。</p>
</div><ul>
<li>NVIDIA Invested in These 2 AI Stocks, Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>NVIDIA 投资了这两只人工智能股票，你应该投资吗？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on Roche</strong></p>
<div class="lb-trans"><p><strong>获取我们对罗氏的最新分析</strong></p>
</div><h2>Roche Company Profile</h2>
<div class="lb-trans"><h2>罗氏公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.</p>
<div class="lb-trans"><p>罗氏控股公司是一家总部位于巴塞尔的瑞士跨国医疗保健公司，成立于 1896 年，由弗里茨·霍夫曼 - 拉·罗氏创立。该公司主要通过两个互补的部门运营——制药和诊断，并以将药物开发与诊断能力相结合以推动个性化医疗而闻名。在美国和其他国际市场，股票以美国存托凭证的形式交易，代码为 RHHBY OTCMKTS: RHHBY。</p>
</div><p>In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.</p>
<div class="lb-trans"><p>在制药领域，罗氏专注于开发和商业化处方药，涵盖包括肿瘤学、免疫学、传染病和神经科学等治疗领域，特别强调靶向生物制剂和个性化疗法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Roche</li>
<li>Stock market legend warns: “An Ominous Day Is Coming for the Markets…”</li>
<li>Another reason you need to own gold… [running out]</li>
<li>Trump’s Final Shocking Act Begins February 24</li>
<li>NEW: Gold makes history</li>
<li>Deutsche Bank Just Raised Their Gold Target to $6,000</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>股票市场传奇警告：“市场即将迎来不祥的一天……”</li>
<li>你需要拥有黄金的另一个理由… [即将耗尽]</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>新消息：黄金创历史新高</li>
<li>德意志银行刚刚将其黄金目标上调至 6,000 美元</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RHHBY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 RHHBY 吗？</strong> 访问 HoldingsChannel.com，获取罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=OTCMKTS&amp;Symbol=RHHBY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Roche Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在罗氏吗？</h2>
</div><p>Before you consider Roche, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑罗氏之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而罗氏并不在名单上。</p>
</div><p>While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然罗氏目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sentinel Trust Co. LBA Buys Shares of 21,507 Roche Holding AG $RHHBY

Market Beat

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

ROCHE HOLDINGS AG

医药突破 ETF - ALPS

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

罗氏(ADR)

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

Sentinel Trust Co. LBA 购买了 21,507 股罗氏 (ADR) 的股票$RHHBY